Ro’s weight loss business more than doubled in the last year. Now it’s trying to prove its program worksnews2024-12-04T13:00:20+00:00December 4th, 2024|Endpoints News|
Dewpoint partners its ALS program, eyes JPM to raise a Series Dnews2024-12-04T13:00:06+00:00December 4th, 2024|Endpoints News|
Lilly wins head-to-head weight loss trial against Novo Nordisknews2024-12-04T11:45:47+00:00December 4th, 2024|Endpoints News|
GSK makes another ADC deal, this time with BioNTech’s partner DualityBionews2024-12-04T08:28:36+00:00December 4th, 2024|Endpoints News|
Lilly removes body mass ranges from FDA label for weight loss drugnews2024-12-03T20:30:12+00:00December 3rd, 2024|Endpoints News|
GSK terminates Phase 2 trial of HBV therapeutic vaccinenews2024-12-03T20:23:03+00:00December 3rd, 2024|Endpoints News|
Kiromic and SEC settle over undisclosed clinical trial holdsnews2024-12-03T19:50:13+00:00December 3rd, 2024|Endpoints News|
Eli Lilly, Pfizer stress independence of telehealth partners in response to senatorsnews2024-12-03T19:40:36+00:00December 3rd, 2024|Endpoints News|
Coherus makes final, $483M pivot away from biosimilarsnews2024-12-03T18:44:02+00:00December 3rd, 2024|Endpoints News|
Takeda to pay $200M for rights to anemia drug from Kerosnews2024-12-03T12:00:51+00:00December 3rd, 2024|Endpoints News|
